1. Pharmaxis
  2. Home
  3. Important Areas
  4. Health Professionals

Health Professionals

Aridol / Osmohale

Pharmaxis' first product available in market is a bronchial provocation test called Aridol or Osmohale. It is approved in Australia, UK, Europe and South Korea and the United States for identifying airway hyperresponsiveness, a key clinical feature of asthma.

For information regarding the availability of Aridol please refer to our Distributors.

For information regarding Aridol please see the Aridol website or contact Medical Information (below).

Bronchitol

Bronchitol is Pharmaxis' second product in development. Bronchitol, is a drug designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions. Bronchitol hydrates the lungs, helps restore normal lung clearance, and allows patients to clear mucus more effectively. Pharmaxis is developing Bronchitol for diseases including cystic fibrosis and bronchiectasis. Bronchitol is a proprietary formulation of mannitol administered as a dry powder in a convenient hand-held inhaler. Bronchitol for the treatment of cystic fibrosis has been approved for use in Australia, and in Europe it has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP). It is currently in ongoing clinical trials in patients with bronchiectasis.

For information on Bronchitol, please see a brief overview of Bronchitol on the Product Information page of our website, or for further detailed medical information on Bronchitol please contact Medical Information (below).
For information about how you may access Bronchitol for your patients for compassionate use, please visit the Named Patient Program section of our website or contact Medical Information:

For information on clinical trials being run by Pharmaxis, please visit the Clinical Trials section of our website or for further details about the progress of clinical trials being undertaken by Pharmaxis, please contact Medical Information (below).

 

Medical Information

For information related to our products, clinical trials or medical research, contact:
Phone: +61 2 9454 7226

Email Address
:

med.info@pharmaxis.com.au


 

Adverse Events

For reporting of any Adverse Events please email

adverse.events@pharmaxis.com.au

or fax +61 2 9454 7255



MEDICAL INFORMATION

For information related to our products, clinical trials or medical research, contact:

Phone: +61 2 9454 7226

Email Address
med.info@pharmaxis.com.au